HKI-272

DRUG4 trials

Sponsors

Puma Biotechnology, Inc., Dana-Farber Cancer Institute

Conditions

Advanced Breast CancerAdvanced Malignant Solid TumorsBreast CancerBreast NeoplasmsCarcinoma, Non-Small-Cell LungLung Neoplasms

Phase 1

A Phase 1/2 Study Of HKI-272 (Neratinib) in Combination With Trastuzumab (Herceptin) In Subjects With Advanced Breast Cancer

CompletedNCT00398567

Puma Biotechnology, Inc.Advanced Breast Cancer

Start: 2007-04-04End: 2018-03-02Updated: 2018-07-24

A Phase 1/2 Study of HKI-272 (Neratinib) in Combination With Paclitaxel (Taxol) in Subjects With Solid Tumors and Breast Cancer

CompletedNCT00445458

Puma Biotechnology, Inc.Advanced Breast Cancer, Advanced Malignant Solid Tumors, Breast Neoplasms

Start: 2007-09-11End: 2018-02-07Updated: 2018-07-26

Phase 2

Study Evaluating the Safety Of HKI-272 (Neratinib) In Subjects With Advanced Non-Small Cell Lung Cancer

CompletedNCT00266877

Puma Biotechnology, Inc.Carcinoma, Non-Small-Cell Lung, Lung Neoplasms

Start: 2005-12-31End: 2009-01-31Updated: 2018-04-13

HKI-272 for HER2-Positive Breast Cancer and Brain Metastases

CompletedNCT01494662

Dana-Farber Cancer InstituteBreast Cancer

Start: 2012-02-01End: 2024-04-19Updated: 2026-01-23

Related Papers

Abstract P5-05-03: Neratinib-based combination treatments for patients with HER2-positive breast cancer brain metastases

Clinical Cancer Research2025-06-13

Neratinib Plus Capecitabine Versus Lapatinib Plus Capecitabine in HER2-Positive Metastatic Breast Cancer Previously Treated With ≥ 2 HER2-Directed Regimens: Phase III NALA Trial

Journal of Clinical Oncology2020-07-17586 citations

Abstract P2-20-01: Impact of neratinib on development and progression of central nervous system (CNS) metastases in patients with HER2-positive metastatic breast cancer (MBC): Findings from the NALA, NEfERT-T, and TBCRC 022 trials

Cancer Research2020-02-156 citations

Pre- and Postoperative Neratinib for HER2-Positive Breast Cancer Brain Metastases: Translational Breast Cancer Research Consortium 022.

2019-08-2221 citations

THER-12. PRECLINICAL EVALUATION OF NERATINIB PLUS T-DM1 IN ORTHOTOPIC PDX MODELS OF HER2-POSITIVE BREAST CANCER BRAIN METASTASES

Neuro-Oncology Advances2019-08-013 citations

Abstract 4832: Preclinical evaluation of neratinib plus T-DM1 in orthotopic PDX models of HER2-positive breast cancer brain metastases

Cancer Research2019-07-014 citations

Abstract 4832: Preclinical evaluation of neratinib plus T-DM1 in orthotopic PDX models of HER2-positive breast cancer brain metastases

Experimental and Molecular Therapeutics2019-07-01

Abstract P5-21-17: Efficacy, safety and tolerability of neratinib-based therapy in patients from Asia with metastatic HER2+ breast cancer and other solid tumors: A pooled analysis of 6 clinical trials

Cancer Research2018-02-152 citations

TBCRC 022: Phase II trial of neratinib + capecitabine for patients (Pts) with human epidermal growth factor receptor 2 (HER2+) breast cancer brain metastases (BCBM).

Journal of Clinical Oncology2017-05-2036 citations

TBCRC 022: Phase II trial of neratinib for patients (Pts) with human epidermal growth factor receptor 2 (HER2+) breast cancer and brain metastases (BCBM).

Journal of Clinical Oncology2014-05-208 citations